Breast Cancer & Cytodyn: Our Dr. Ueno: Dr. Uen
Post# of 155372
(Total Views: 624)
Posted On: 11/10/2024 12:10:34 AM
Breast Cancer & Cytodyn:
Our Dr. Ueno:
Dr. Ueno is currently the Director at the University of Hawaii Cancer Center, having previously served as the Executive Director of the Inflammatory Breast Cancer Program and the Clinic Chief of the Translational Breast Cancer Research at the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center.
Dr. Yam:
Yam is leader of the triple-negative breast cancer (TNBC) working group and Director of Team Science and Innovation in the Department of Breast Medical Oncology at MD Anderson.
Sept. Letter:
I am pleased to announce that CytoDyn is working with a team of experts to resume the exploration of Triple-Negative Breast Cancer (“TNBC”), including colleagues from the University of Hawaii Cancer Center, MD Anderson Cancer Center, and the Pennsylvania Cancer and Regenerative Medicine Research Center.
__
Could say odds are Dr. Pestell now rejoins.
Especially given the past press release mgt addressed to him.
A public apology as 1 of the stipulations to later rejoin?
Entire Tnbc collab team giving reports directly to Max, so all work is verified to GSK @ a later date?
( hmmm )
So the Tnbc collaboration could have a deeper intent to it than just the news release.
Our Dr. Ueno:
Dr. Ueno is currently the Director at the University of Hawaii Cancer Center, having previously served as the Executive Director of the Inflammatory Breast Cancer Program and the Clinic Chief of the Translational Breast Cancer Research at the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center.
Dr. Yam:
Yam is leader of the triple-negative breast cancer (TNBC) working group and Director of Team Science and Innovation in the Department of Breast Medical Oncology at MD Anderson.
Sept. Letter:
I am pleased to announce that CytoDyn is working with a team of experts to resume the exploration of Triple-Negative Breast Cancer (“TNBC”), including colleagues from the University of Hawaii Cancer Center, MD Anderson Cancer Center, and the Pennsylvania Cancer and Regenerative Medicine Research Center.
__
Could say odds are Dr. Pestell now rejoins.
Especially given the past press release mgt addressed to him.
A public apology as 1 of the stipulations to later rejoin?
Entire Tnbc collab team giving reports directly to Max, so all work is verified to GSK @ a later date?
( hmmm )
So the Tnbc collaboration could have a deeper intent to it than just the news release.
(7)
(0)